Anzeige
Mehr »
Dienstag, 22.07.2025 - Börsentäglich über 12.000 News
Alarm am Metallmarkt: Kupfer unter Strom: USA rüsten sich - was das für Anleger bedeutet
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D54P | ISIN: US21833P3010 | Ticker-Symbol: 3371
Tradegate
21.07.25 | 16:40
7,800 Euro
+6,12 % +0,450
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CORBUS PHARMACEUTICALS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
CORBUS PHARMACEUTICALS HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,3007,35021.07.
7,2007,50021.07.

Aktuelle News zur CORBUS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.06.Corbus begins multiple ascending dose portion of CRB-913 obesity trial2
CORBUS PHARMACEUTICALS Aktie jetzt für 0€ handeln
30.06.Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity108No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals...
► Artikel lesen
25.06.Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab177Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck Squamous Cell Carcinoma (HNSCC) and...
► Artikel lesen
24.06.Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium4
21.05.Mizuho cuts Corbus Pharma stock target to $32, keeps Outperform7
19.05.Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report2
19.05.Corbus Pharmaceuticals names industry veteran Rachelle Jacques as board chair7
19.05.Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair7
16.05.Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?5
06.05.Corbus Pharmaceuticals Holdings, Inc. - 10-Q, Quarterly Report1
06.05.Corbus Pharmaceuticals Holdings, Inc. Q1 Loss Increases, Misses Estimates3
06.05.Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report1
06.05.Corbus Pharmaceuticals GAAP EPS of -$1.39 misses by $0.283
28.03.Corbus begins Phase 1 trial for new obesity treatment CRB-9134
28.03.Corbus beginnt Phase-1-Studie für neue Adipositas-Behandlung CRB-9135
28.03.Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity259CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled...
► Artikel lesen
18.03.Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report5
11.03.Corbus Pharmaceuticals Holdings, Inc. - 10-K, Annual Report4
11.03.Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report1
11.03.Corbus Pharmaceuticals GAAP EPS of -$0.78 beats by $0.504
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1